A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

@article{Kipnes2010AOS,
  title={A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes},
  author={Mark S. Kipnes and Priscilla A. Hollander and Ken Fujioka and Ira Gantz and Thomas L Seck and Ngozi Erondu and Yue Shentu and Kaifeng Lu and Shailaja Suryawanshi and M Chou and Amy O. Johnson‐Levonas and S. B. Heymsfield and Deborah R. Shapiro and Keith D. Kaufman and John M. Amatruda},
  journal={Diabetes},
  year={2010},
  volume={12}
}
Aim: To evaluate the efficacy and safety of taranabant in overweight and obese patients with type 2 diabetes mellitus (T2DM). 
View on Wiley
onlinelibrary.wiley.com
44 Citations
Highly Influential Citations
2
Background Citations
10
Results Citations
3

44 Citations

Citation Type

Citation Type

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
TLDR
Taranabant at the 2- and 4-mg dose was effective in achieving clinically significant weight loss over 2 years and was associated with dose-related increases in adverse experiences.
Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes
To quantify the effect of weight loss on glycated haemoglobin (HbA1c) at group level, based on data from published weight loss trials in overweight and obese patients with type 2 diabetes (T2D).
The cannabinoid‐1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice
TLDR
The aim of this study was to evaluate the potential application of taranabant, a cannabinoid type 1 (CB1) inverse agonist using mouse models mimicking the symptoms of IBS‐C.
A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low‐Calorie Diet
TLDR
This 1‐year, randomized, placebo‐controlled trial evaluated the safety and efficacy of weight maintenance counseling combined with either placebo or the cannabinoid‐1 receptor inverse agonist, taranabant, for sustaining prior weight loss achieved on a low‐calorie diet.
Possible Role of Adipose Tissue and Endocannabinoid System in COVID‐19 Pathogenesis: Can Rimonabant Return?
ABSTRACT This is the main conclusion of a recent study describing a strong relationship between the degree of obesity and the severity of COVID‐19 infection. Obesity has various negative consequences…
New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier?
Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs
TLDR
Preclinical and clinical studies suggest that ligands targeting the CB1 may retain the therapeutic potential of rimonabant without the negative side effect profile, and clearly point out the cannabinoid CB1 as a potential effective target for the treatment of obesity.
Pharmacotherapies for Obesity: Past, Current, and Future Therapies
TLDR
Of the Phase III pharmacotherapies, lorcaserin, taranabant, topiramate and bupropion with naltrexone have demonstrated significant weight loss compared to placebo at ≥12 months, and some pharmacotherAPies have also demonstrated clinical benefits.
Endocannabinoids and obesity.
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons
TLDR
Targeting the molecular pathways that mediate the beneficial effects of calorie restriction and exercise may represent an alternative therapeutic approach for the treatment of chronic metabolic disorders such as obesity.
...
...

References

SHOWING 1-10 OF 72 REFERENCES
A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin
  • C. Berne
  • Medicine, Biology
    Diabetic medicine : a journal of the British Diabetic Association
  • 2005
Aims  To assess the effects of orlistat vs. placebo, in combination with a weight management programme, on weight loss and metabolic control in obese patients with Type 2 diabetes.
Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?
  • S. Tonstad
  • Medicine
    Nature Clinical Practice Cardiovascular Medicine
  • 2006
Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study
TLDR
All three doses of taranabant-induced clinically meaningful and statistically significant weight loss were found to be valid and effective in obese and overweight patients.
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
TLDR
Taranabant at the 2- and 4-mg dose was effective in achieving clinically significant weight loss over 2 years and was associated with dose-related increases in adverse experiences.
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study
TLDR
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients in the Swedish Multimorbidity Study is illustrated.
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
TLDR
Rimonabant 20 mg over 2 years promoted clinically relevant and durable weight loss and improvements in cardiometabolic risk factors and produced clinically meaningful improvements in all Impact of Weight on Quality of Life-Lite questionnaire domain scores at 2 years.
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
TLDR
Selective CB1-receptor blockade with rimonabant significantly reduces body weight and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
TLDR
Orlistat is a useful adjunctive treatment for producing weight loss and improving glycemic control, serum lipid levels, and blood pressure in obese patients with type 2 diabetes who are being treated with metformin.
Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study
TLDR
Orlistat is an effective treatment modality in obese patients with type 2 diabetes with respect to clinically meaningful weight loss and maintenance of weight loss, improved glycemic control, and improved lipid profile.
...
...